Stéphane Bancel
Summary
Stéphane Bancel is Moderna’s founding Chief Executive Officer and has led the company since joining as CEO in 2011. ([modernatx.com](https://www.modernatx.com/about-us/our-story?utm_source=openai))
Biography
Bancel is a French business executive with a Master of Engineering from École Centrale Paris, a Master of Science in Chemical Engineering from the University of Minnesota, and an MBA from Harvard Business School. He previously spent about five years as CEO of French diagnostics company bioMérieux SA. Before that, he held several positions at Eli Lilly, including Managing Director of Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000130817926000081/mrna-20260316.htm?utm_source=openai)) At Moderna, Bancel chairs the Executive Committee and is responsible for the company’s strategy and operations. His tenure covers Moderna’s transformation from a privately held biotechnology company into a commercial vaccine maker, including the development and launch of its COVID-19 vaccine and expansion into respiratory vaccines, oncology, and rare diseases. He also serves on Moderna’s board of directors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000022/mrna-20241231.htm))
Notable achievements
- Led Moderna through the development and commercialization of Spikevax, one of the first widely authorized mRNA COVID-19 vaccines. ([fda.gov](https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/moderna-covid-19-vaccine?utm_source=openai))
- Oversaw Moderna’s expansion into commercial respiratory vaccines, including FDA approval of the RSV vaccine mRESVIA in 2024. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-roundup-may-31-2024?utm_source=openai))
- Led the company’s next-generation COVID-19 vaccine program, including FDA approval of mNEXSPIKE in 2025. ([apnews.com](https://apnews.com/article/84293ee6799dfbbe4e66dce06022afae?utm_source=openai))
- Oversaw the 2026 FDA approval of MFLUSIVA, Moderna’s mRNA seasonal influenza vaccine for adults aged 50 and older. ([fda.gov](https://www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva?utm_source=openai))
- Directed a broad cost-reduction and pipeline-prioritization program intended to reduce operating expenses and move Moderna toward targeted cash breakeven in 2028. ([modernatx.com](https://www.modernatx.com/en-US/media-center/all-media/blogs/moderna-2025-shareholder-letter?utm_source=openai))
Problem areas / controversies
- Moderna’s post-pandemic revenue decline created pressure on the company’s strategy, cash use, share price, and need for substantial cost reductions. ([apnews.com](https://apnews.com/article/f7564b5f3f7802e7943f8fe16bec0738?utm_source=openai))
- The company discontinued its congenital CMV vaccine program in October 2025 after a Phase 3 trial failed to meet its primary efficacy endpoint. ([modernatx.com](https://www.modernatx.com/en-US/media-center/all-media/blogs/phase-3-cmv-vaccine-readout-reflections?utm_source=openai))
- The FDA initially issued a refusal-to-file notice for Moderna’s seasonal flu vaccine application over concerns about the design of its comparative clinical trial, although the agency later accepted a revised application and approved MFLUSIVA on August 5, 2026. ([apnews.com](https://apnews.com/article/2fc551cb2fb45735e67db0a4e2e2b0fb))
- Moderna agreed to pay $950 million in July 2026 to settle worldwide patent litigation involving lipid nanoparticle technology used in Spikevax and mRESVIA. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm?utm_source=openai))